Genomic profiling of small-cell lung cancer: the era of targeted therapies (Q26826915)

K. Tsuchihara

series ordinal

2

1 reference

K. Goto

series ordinal

3

1 reference

language of work or name

1 reference

June 2015

1 reference

Japanese Journal of Clinical Oncology

published in

1 reference

volume

45

1 reference

issue

6

1 reference

page(s)

513-9

1 reference

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Novel strategies for the treatment of small-cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Clinical trial design in small cell lung cancer: surrogate end points and statistical evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Genomic landscape of non-small cell lung cancer in smokers and never-smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

KIF5B-RET fusions in lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Comprehensive genomic characterization of squamous cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

A small-cell lung cancer genome with complex signatures of tobacco exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Genetic changes in small cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Molecular profiling of small cell lung cancer in a Japanese cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Epidermal growth factor receptor mutations in small cell lung cancer patients who received surgical resection in China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

EGFR mutation in gefitinib-responsive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

EGFR mutations in small-cell lung cancers in patients who have never smoked.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Optimal use of targeted agents for advanced gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

CD117 immunoreactivity in stage I adenocarcinoma and squamous cell carcinoma of the lung: relevance to prognosis in a subset of adenocarcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Therapeutic efficacy of c-kit-targeted radioimmunotherapy using 90Y-labeled anti-c-kit antibodies in a mouse model of small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Production of immunoreactive insulin-like growth factor-I (IGF-I) and IGF-I binding proteins by human lung tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Small cell lung carcinoma (SCLC): the angiogenic phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the Europea

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Mammalian achaete-scute homolog 1 is required for the early development of olfactory and autonomic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Two rat homologues of Drosophila achaete-scute specifically expressed in neuronal precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

An achaete-scute homologue essential for neuroendocrine differentiation in the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Targeting the phosphoinositide 3-kinase p110-α isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Phase II study of everolimus (RAD001) in previously treated small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Vandetanib for the treatment of medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

A framework for identification of actionable cancer genome dependencies in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Awakening guardian angels: drugging the p53 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

7 January 2021

Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

7 January 2021

Bringing the genomic landscape of small-cell lung cancer into focus

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

7 January 2021

A genetic snapshot of small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

7 January 2021

Efficacy of surgery and imatinib mesylate in the treatment of advanced gastrointestinal stromal tumor: a systematic review.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

7 January 2021

Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

7 January 2021

Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

7 January 2021

Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

7 January 2021

Targeting Rb mutant cancers by inactivating TSC2.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

7 January 2021

Expression and mutation of the c-kit gene and correlation with prognosis of small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV017

7 January 2021